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Flow Cytometric Characterization and Clinical Outcome of CD4+
T-Cell Lymphoma in Dogs: 67 Cases
P.R. Avery, J. Burton, J.L. Bromberek, D.M. Seelig, R. Elmslie, S. Correa, E.J. Ehrhart, P.S. Morley,
and A.C. Avery
Background: Canine T-cell lymphoma (TCL) is conventionally considered an aggressive disease, but some forms are
histologically and clinically indolent. CD4 TCL is reported to be the most common subtype of TCL. We assessed flow
cytometric characteristics, histologic features when available, and clinical outcomes of CD4+ TCL to determine if flow
cytometry can be used to subclassify this group of lymphomas.
Objective: To test the hypothesis that canine CD4+ T-cell lymphoma (TCL) is a homogeneous group of lymphomas
with an aggressive clinical course.
Animals: Sixty-seven dogs diagnosed with CD4+ TCL by flow cytometry and treated at 1 of 3 oncology referral clinics.
Methods: Retrospective multivariable analysis of outcome in canine CD4+ TCL including patient characteristics, treat-
ment, and flow cytometric features.
Results: The majority of CD4+ TCL were CD45+, expressed low class II MHC, and exhibited an aggressive clinical
course independent of treatment regimen (median survival, 159 days). Histologically, CD4+ TCL were classified as lym-
phoblastic or peripheral T cell. Size of the neoplastic lymphocytes had a modest effect on both PFI and survival in this
group. A small number of CD4+ TCL were CD45 and class II MHC high, and exhibited an apparently more indolent
clinical course (median survival not yet reached).
Conclusions and Clinical Importance: Although the majority of CD4+ TCL in dogs had uniform clinical and flow cyto-
metric features and an aggressive clinical course, a subset had a unique immunophenotype that predicts significantly longer
survival. This finding strengthens the utility of flow cytometry to aid in the stratification of canine lymphoma.
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Lymphoma is the most common hematologic malig-nancy in dogs and has long been subdivided into
T- and B-cell phenotypes, with T-cell subtypes typi-
cally considered to have a more aggressive clinical
course. Further subclassification within the T-cell
phenotype has identified important subtypes that are
associated with both aggressive disease (pleomorphic
mixed/peripheral T cell, plasmacytoid, T-cell lympho-
blastic) and indolent disease (small clear cell/T zone
lymphoma).1,2 This distinction, important for both
prognosis and rational selection of chemotherapy
protocol, is currently made by histologic examination
of tissue specimens.
Flow cytometry is a critical tool in human medicine
for diagnosing and characterizing cases of lymphoma.
Despite its expanding diagnostic role in veterinary medi-
cine, there are few flow cytometric descriptions of canine
lymphoma.3–7 In the authors’ experience, CD4+ T cell
lymphoma (TCL) is the most common T-cell immuno-
phenotype seen in aspirates from canine peripheral
lymph nodes and this is consistent with 2 small case ser-
ies of canine TCL.4,7 In a very small number of cases
with concurrent Kiel cytologic classification, CD4+
TCL were described as small clear cell/T zone, lympho-
blastic, and pleomorphic mixed cell/peripheral T-cell
subtypes.3,4 When lymphoma restricted to the Boxer
breed was examined, >80% of cases were T-cell origin
and the majority were of the CD4+ phenotype.5,8 In
these studies and in a larger study of canine lymphoma,
the CD4+ phenotype appeared to be associated with an
aggressive clinical course,5,8,9 but to the authors’ knowl-
edge, no studies have described large numbers of cases
of canine TCL based on the CD4+ immunophenotype.
The purpose of this study was to further classify canine
CD4+ TCL with peripheral lymph node involvement by
examining clinical characteristics, flow cytometric
parameters associated with clinical outcome, and histo-
logic classification when available.
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Materials and Methods
Case Selection
Cases submitted to the Clinical Immunology Laboratory at
CSU between January 1, 2008 and February 1, 2012 comprised
the population of patients for this study. Of these, 168 met the
inclusion criteria, which were as follows: (1) cytologic or histo-
logic diagnosis of lymphoma; and (2) >65% of the large cells or
>80% of the entire population expressing CD4. Forty percent of
these cases (67) were derived from 3 referral clinics, with the
remainder coming from 57 other clinics. Because of the difficulty
in obtaining consistent clinical follow-up from multiple clinics,
the 67 cases from 3 referral centers were chosen for further
analysis. The 67 cases chosen for follow-up were not significantly
different from the remaining 101 cases with regard to age, breed
distribution, sex, and the presence of selected clinical characteris-
tics (Table 1). Data extracted from the medical records included
patient age, sex, breed, date of diagnosis, date of treatment initia-
tion, staging tests performed, the presence of hypercalcemia at
diagnosis, clinical substage, treatment protocol, time to progres-
sion of disease, and date of death.
Flow Cytometry
Samples were submitted based on palpable peripheral lymph-
adenopathy. Multiple fine needle aspirates from the lymph node
were placed in isotonic saline with 10% canine serum and
submitted immediately or shipped overnight on ice. Lymph node
samples were prepared as described previously.10 The lymph node
suspension was centrifuged and resuspended in 1 mL of lysis buf-
fer (0.15 M NH4CL, 1 M KHO3, 0.1 mM Na2 EDTA, 1 N HCL
at a pH of 7.2–7.4) for 5 minutes at room temperature. Samples
were subsequently centrifuged, lysed a second time, and resus-
pended in 200 lL of phosphate-buffered saline (PBS)-2% fetal
bovine serum (FBS). A 96-well plate was used in which 25 lL of
cell suspension was added to individual wells plus 25 lL of one
of the combinations of antibodies. Antibody combinations were
(1) None, (2) M IgG1-FITC/CD45-PE, (3) CD18-FITC/M IgG1-
PE, (4) CD4-FITC/CD8-PE, (5) CD5-FITC/CD21-PE, (6) CD3-
FITC/CD45-PE, (7) CD4-FITC/CD14-PE, and (8) Class II
MHC-FITC/CD34-PE.a Samples were incubated for 15 minutes
at room temperature and then washed twice. Samples then were
resuspended in PBS-2% FBS with 10 lg/mL of propidium iodide
(PI) for dead cell exclusion, and analyzed within 1 hour. Samples
with >50% PI-positive cells were excluded from further analysis.
Samples were acquired on a Coulter XL flow cytometer. All data
analysis was carried out by Kaluza software.b
Immunohistochemistry and Histologic Classification
For immunophenotyping of tissue samples, 5-lm sections from
formalin-fixed, paraffin-embedded tissues were cut and immuno-
stained utilizing antibodies directed against the CD3 antigen to
stain T cells (clone LN10c ) or either Pax5 or CD79a antigen to
stain B cells (clone DAK-Pax5 and HM57d). Deparaffinization,
antigen retrieval, immunohistochemical (IHC) staining, and
counterstaining were performed on the Bond maX Automated
Staining System by the Bond Polymer Detection System.c Anti-
gen retrieval was accomplished on line using Bond Epitope
Retrieval Solution 2 (EDTA based, pH 9.0 solution) using a 30-
minute incubation.
Biopsies were available for 15 cases. H&E, as well as IHC
from these 15 cases, and an additional 13 cases of T-cell lym-
phoma with a different immunophenotype (companion paper,
Seelig et ale) were reviewed by 2 board-certified veterinary
pathologists (D.M.S. and E.J.E.) and classified according to
WHO criteria.11 At the time of review, the pathologists were
blinded to the results of flow cytometry and clinical data. To
make their diagnosis, the pathologists used previously described
histologic and immunohistologic criteria.11
Data Analyses
Progression-free interval (PFI) and overall survival (OS) were
calculated in days from the time of treatment initiation until pro-
gressive disease or death, respectively. Dogs still alive at the time
of data analysis or lost to follow-up were censored at the last
date reported to be alive. Dogs that had died or were euthanized
were considered to be dead either secondary to their treatment or
disease. Dogs treated with prednisone only were excluded from
PFI analysis, because treatment did not result in resolution of
clinical signs. Clinical data at the time of presentation, including
signalment, weight, the presence of hypercalcemia, and imaging
assessment of a mediastinal mass and clinical substage were fur-
ther evaluated for effect on PFI and survival. When no informa-
tion was available, a normal finding was not inferred, and the
patient was excluded from this analysis. In addition, patient
demographics including the dog’s age, sex, breed, and clinic
where treated were considered as potential confounders.
Descriptive statistics were calculated for all variables collected
at baseline. Age at diagnosis was dichotomized at the median
for all uni- and multivariable analyses. Log rank test and
Kaplan-Meier plots were used to evaluate whether any baseline
variable was associated with PFI or survival. Multivariable Cox
proportional hazard analyses were performed in a backward step-
Table 1. Characteristics of the dogs in this study, and
comparison of selected features with dogs not included
in the study
Parameter
Study Population
(n = 67)
Dogs Not in
Study
(n = 101)a P Valueb
Age (years)
Mean  SD 7.2  2.1 7.2  2.5 .26
Sex
Male 2 (3%) 8 (8%) .053
Neutered male 34 (51%) 52 (52%)
Female 6 (9%) 1 (1%)
Spayed female 25 (37%) 36 (36%)
Weight (kg)
Mean  SD 29.6  12.9 N/A N/A
Breed
Mixed breed 17 (25%) 14 (14%) .29
Boxer 13 (19%) 26 (26%)
Golden Retriever 10 (15%) 16 (16%)
Other 27 (40%) 45 (45%)
Substage
a 54 (81%) N/A N/A
b 13 (19%) N/A
Calcium status
Elevated 28 (50%) 23 (68%) .13
Normal 27 (50%) 11 (32%)
Mediastinal mass
Present 15 (43%) 3 (30%) .2
Absent 20 (57%) 12 (70%)
aNumbers will not add up to the total cases because of missing
information for some patients. For example, information about
sex was only available for 97 of the 101 patients.
bCalculated by chi-square analysis.
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wise manner. An initial model was constructed with all potential
prognostic variables with P values <.20 on univariable analysis as
well as the potential confounders breed, clinic, and treatment.
Backward selection was conducted until all remaining variables
had P values <.05. Finally, reanalysis was conducted adding
prognostic indicators one-by-one to determine if they were signif-
icant in a multivariable setting; only significant variables
remained in the final model. Except where otherwise noted, all
statistical analyses were performed by SAS 9.2f and P values <.05
were considered significant.
Results
Flow Cytometric Characterization
Sixty-one of the 67 CD4-positive cases were charac-
terized by uniform expression of CD3, CD45, low
levels of MHC class II (median fluorescence intensity
[MFI] 1.2), and absent expression of CD21 (referred
to subsequently as CD4+/CD45+). CD5 expression
was variable in this group with 26 cases categorized
as lacking the expression of CD5, whereas 34 were
uniformly CD5 positive. The median percentage of
CD5+ cells in those cases categorized as lacking CD5
expression was 2.1% (range 0–20%). The remaining 6
cases had unique phenotypic features characterized by
high MHC class II expression (MFI 22), coexpression
of CD21 and loss of CD45 expression (referred to
subsequently as CD4+/CD45; Fig 1). The median
percentage of cells negative for CD45 was 96%
(range 93–98%), whereas the median percentage of
cells positive for CD21 was 94% (range 60–97%). All
6 of these cases uniformly expressed both CD3 and
CD5.
Patient Demographics
Table 1 shows demographic information for all 67
dogs in the study. For the 61 dogs with CD4+/CD45+
TCL, the median age was 7 years (range 3–13 years).
Twenty-seven cases were female (6 intact, 21 neutered)
and 34 cases were male (2 intact, 32 neutered). Mixed
breed dogs were the most frequently represented breed
(n = 16; 26%) followed by Boxers (n = 13; 21%) and
Golden Retrievers (n = 8; 13%). Other breeds repre-
sented by >1 case included English Bulldogs, Labrador
Retrievers, Shetland Sheepdogs, Rottweilers, and Saint
Bernards (all 3%). Median age of the 6 dogs with
CD4+/CD45 lymphoma was 8.9 years (range 6–
10 years) and 4 were female-neutered and 2 were male-
neutered. Two CD4+/CD45 dogs were Golden
Retrievers, whereas there was 1 each of Australian
Shepherd, Bernese Mountain Dog, Chihuahua, and
mixed breed.
A
B
Fig 1. Typical flow cytometric properties of CD4+/CD45+ (A) and CD4+/CD45 (B) subsets of CD4+ lymphoma. CD45 expression is
shown in the right panel. CD45 cases expressed high levels of class II MHC compared with CD4+/CD45+ dogs (left panel), and higher
levels of CD21 (middle panel).
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Summary of Endpoints
After excluding 12 dogs that were treated only with
prednisone (1 CD4+/CD45, 11 CD4+/CD45+), analy-
ses evaluating PFI included 55 dogs. Of these dogs, 2
of 5 (40%) CD4+/CD45 dogs and 43 of 50 (86%)
CD4+/CD45+ dogs developed progressive disease.
Overall, 10 dogs were censored; 5 were alive without
progressive disease at the end of the study period (3
CD4+/CD45, 2 CD4+/CD45+); 1 CD4+/CD45+ was
lost to follow-up; and 4 CD4+/CD45+ died or were
euthanized before progressive disease was noted. All
67 dogs were able to be analyzed for overall survival;
3 of 6 (50%) CD4+/CD45 dogs and 54 of 61 (89%)
CD4+/CD45+ died or were euthanized during the
study period. Censoring occurred for 7 dogs that were
alive at the end of the study period (3 CD4+/CD45,
4 CD4+/CD45+) and 3 CD4+/CD45+ dogs that were
lost to follow-up. Median follow-up time did not differ
significantly between CD4+/CD45+ dogs and CD4+/
CD45 dogs (548 days [95% CI, 361–557] for CD4+/
CD45+ dogs, 405 days [95% CI, 185–557] for
CD4+/CD45 dogs; log rank P = .8751).
CD45 T-Cell Lymphomas Exhibit Different
Clinical Behavior
Three of the 6 CD4+/CD45 phenotype dogs were
alive without progression at the end of the study, sug-
gesting that some of these cases have a more indolent
clinical course. Median PFI and OS in the majority
CD4+/CD45+ group were 91 days (range 25–557 days)
and 159 days (range 4–557 days), respectively. Median
PFI and OS of the 6 CD4+/CD45 dogs could not be
calculated because 3 of these dogs were alive at 228,
303, and 1043 days of follow-up (Fig 2). During the
study period, 2 CD4+/CD45 dogs developed progres-
sive disease (27 and 107 days, subsequently euthanized
for unknown causes at 134 and 188 days) and 1 was
treated with prednisone only and euthanized after
166 days, also for unknown reasons. Concurrent work
in our laboratory has associated the loss of CD45
expression, high MHC class II expression, and
coexpression of CD21 in T-cell lymphomas with T zone
histology and indolent behavior (Seelig et ale). Because
of this apparent difference in biologic behavior and our
concurrent findings, which identify this phenotype as
associated with T zone histology (Seelig et ale), these
cases were removed from all subsequent analysis.
Cell Size and CD5 Expression in CD4+/CD45+
Lymphomas Influences Outcome
When the size of the neoplastic CD4+/CD45+ lym-
phocytes was divided into small and large based on
the median cell size of all cases, there was a significant,
modest impact on both PFI and survival in univariable
analysis (Table 2). Controlling for treatment, large cell
size remained significantly associated with a shortened
PFI. Large cell size was also associated with shortened
overall survival, controlling for treatment, CD5 status,
and substage (Table 2).
CD5 expression was absent in 43% (26 of 60 with
available data) of dogs in the CD4+/CD45+ subset.
Absent CD5 was associated with a significant, modest
impact on survival in univariable analysis without a
significant impact on PFI (Table 2). Controlling
for treatment, cell size, and substage, CD5+ status
remained significantly associated with a shortened
overall survival. All 6 dogs with the CD4+/CD45
phenotype expressed CD5 (not shown in Table 2).
Effect of Clinical Characteristics on Outcome
There were no significant differences comparing PFI
and OS in normocalcemic versus hypercalcemic dogs
in univariable analysis, nor was there a significant dif-
ference in comparing dogs with and without evidence
of a mediastinal mass (Table 2). Full staging was not
performed in most dogs, and accurate assessment of
stage could not be determined in this study. Twenty-
five (37%) of dogs had no staging beyond a CBC and
serum biochemical profile before treatment initiation;
38 (57%) dogs had thoracic radiographs; 3 (4%) dogs
had abdominal radiographs; 12 (22%) dogs had
abdominal ultrasound examinations; and 3 (4%) dogs
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Fig 2. Surface marker expression distinguishes CD4+ lymphomas with distinct clinical courses. Median PFI/survival CD4+/
CD45+ = 91/159 days, CD4+/CD45 = undefined/undefined days.
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had bone marrow aspirates performed. Forty-eight
dogs (79%) were clinically well (substage a) and the
other 13 (21%) dogs were substage b at the time of
diagnosis. Substage did not have a significant impact
on PFI, but there was a significant impact on survival
(Table 2).
Effect of Treatment on Outcome
The dogs with CD45+ lymphoma were treated with
a variety of chemotherapy protocols. Thirty-one (46%)
dogs were treated with a multi agent protocol; 20
(30%) dogs were treated with a CHOP-based protocol
that included vincristine, cyclophosphamide, doxorubi-
cin, prednisone, +/ L-asparaginase; and 11 (16%)
dogs were treated with a MOPP-based protocol con-
sisting of mechlorethamine, vincristine, procarbazine,
prednisone, +/ L-asparaginase. Twenty-four (36%)
dogs were treated with a single-agent protocol plus
prednisone consisting of CCNU (n = 10; 15%), doxo-
rubicin (n = 12; 18%), or chlorambucil (n = 2; 3%).
The remaining 12 (18%) dogs were treated with pred-
nisone only. Three dogs treated at CSU were initially
treated with an investigational chemotherapeutic agent,
which delayed the initiation of definitive treatment by
8–11 days; the start of treatment for these 3 dogs was
recorded as the day they started CHOP (n = 1) or
doxorubicin (n = 2) for the purposes of calculating
PFI and OS. Response rates were not evaluated in this
study because of the variability in assessment between
clinics and the retrospective nature of this study.
Figure 3 shows PFI and survival curves for all 4
treatment groups. Among CD4+/CD45+ dogs, there
was no significant difference in median PFI or survival
comparing dogs treated with MOPP with those treated
with CHOP in univariable analysis (PFI; MOPP,
131 days; CHOP, 109 days; P = .9480; survival;
MOPP, 114 days; CHOP, 237 days; P = .06) or multi-
variable analysis. Progression-free interval, but not
overall survival, was significantly different between
dogs treated with single-agent chemotherapy and those
treated with CHOP (PFI; single, 70 days; CHOP,
109 days; P = .0039). This relationship remained sig-
nificant in multivariable analysis (PFI hazard ratio
[HR], 3.11; 95% CI, 1.53–6.32). Not surprisingly, sur-
vival was significantly different between dogs treated
with prednisone only compared with those treated
with CHOP (survival; prednisone, 80 days; CHOP,
237 days; P < .0001). Controlling for cell size, sub-
stage, and CD5 status, prednisone treatment remained
significantly different from CHOP in terms of survival
(HR, 2.72; 95% CI, 1.11–6.66).
Histologic Characterization
Biopsies of 15 CD4+/CD45+ cases were available
for review. The consensus histologic classification for
10 cases was peripheral T cell not otherwise specified
(PTCL), whereas the remaining 5 cases were classified
as lymphoblastic T cell (LBT; Fig 4). All affected
lymph nodes were characterized by diffuse effacement
by neoplastic cells. Peripheral T cell not otherwise
Table 2. Summary of PFI and survival analysis for selected clinical and immunophenotypic characteristics.
Variable (No. of
Patients)a
Univariable Analysis Multivariable Analysis
PFI
P Value for
PFI Difference
Overall Survival
(Range)
P Value for
Survival Difference
Hazard Ratio
for PFI
Hazard Ratio
for Survival
CD5 expression
Positive (34) 77 (65–111) .1353 143 (92–159) .0056 — 2.5 (1.2–5.1)
Negative (26)b 98 (65–175) 195 (137–314) 1
Cell size
Small (30) 121 (73–191) .0012 206 (146–235) .0146 3.3 (1.6–6.6) 2.2 (1.1–4.3)
Large (31) 77 (44–91) 130 (91–159) 1 1
Multi-agent tx
MOPP (10) 131 (35–266) .0091 114 (35–194) .0003 1.6 (0.6–4.1) 2.0 (0.7–5.3)
Single agent (22) 70 (43–81) 170 (104–218) 3.1 (1.5–6.3) 1.6 (0.7–3.5)
Prednisone (11) — 80 (8–130) — 2.7 (1.1–6.7)
CHOP (18) 109 (91–191) 237 (159–312) 1 1
Calcium status
High (28) 83 (65–182) .5532 141 (95–185) .1323 — —
Normal (22) 113 (73–167) 170 (137–272)
Mediastinal mass
Present (15) 81 (28–113) .0801 130 (40–195) .1762 — —
Absent (18) 140 (65–191) 155 (91–435)
Substage
b (13) 97 (48–204) .7495 106 (20–195) .0085 — 4.1 (1.7–9.9)
a (48) 91 (69–111) 164 (137–210) 1
aNumbers reflect the number of dogs analyzed for overall survival. Fewer animals were analyzed for PFI as the prednisone-treated
patients were not included in this group. Only patients with CD45+ T-cell lymphoma are included in this table.
bNot all values were available for all dogs. For example, in 1 dog, CD5 staining was not performed, so that there are only 60 dogs in
the CD5 outcome analysis.
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specified and LBT were discriminated primarily based
on cell size (intermediate-sized cells in LBT and inter-
mediate-to-large-sized cells in PTCL), degree of pleo-
morphism (low in LBT and high in PTCL), and
number of mitotic figures (very common in LBT and
rare in PTCL). There were no differences in presenta-
tion or in clinical outcome between the 2 groups, but
small sample size may have precluded detection of a
difference. All of the dogs with available tissue had an
aggressive clinical course (median PFI = 85 days, med-
ian survival = 155 days). Biopsies were not available
for any of the 6 dogs with the CD4+/CD45 flow
cytometric staining pattern.
Discussion
Our characterization of the majority of the CD4+
lymphomas (CD4+/CD45+) with peripheral lymph
node involvement in this case series is consistent with
previous studies of canine T-cell lymphoma. The short
median PFI and OS, breed distribution, and incidence
of hypercalcemia and mediastinal masses seen in this
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Fig 3. Progression-free interval (PFI) is not different between treatment groups. Overall survival is significantly different for prednisone
only compared with CHOP. Only dogs with CD4+/CD45+ lymphoma were included in this analysis.
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Fig 4. Histologic and immunohistologic features of the 2 morphologic variants of canine CD4+/CD45+ lymphoma. Five of the 15 cases
of CD4+/CD45+ lymphoma were histologically classified as lymphoblastic T-cell lymphoma (LBT, A–C), whereas 10 were classified as
peripheral T-cell lymphoma (PTCL, D–F). On hematoxylin-and-eosin–stained sections, cases of LBT (A) were characterized by diffuse
effacement of the lymph node architecture by intermediate-sized cells with uniform round-to-oval nuclei and high numbers of mitotic fig-
ures, whereas in PTCL (B), the effacing cells were intermediate-to-large in size with irregularly shaped nuclei, anisokaryosis, and rare
mitotic figures. In both LBT and PTCL, immunohistochemistry confirms the T-cell phenotype of the neoplastic cells through uniform,
heavy anti-CD3 immunoreactivity (B and E, red) and absent-to-scant anti-Pax5 (C, red) or CD79a (F, red) immunoreactivity.
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study are similar to previous reports.12,13 The over-rep-
resentation of Boxers seen here has been reported in
previous studies of canine T-cell lymphoma.5,8 One
study of lymphoma in Boxers utilizing immunocyto-
chemistry reported that 12/22 cases expressed CD4, 6/
22 expressed neither CD4 nor CD8, 1/22 expressed
both CD4 and CD8, and 1/22 expressed CD8 only.5
Although we cannot conclude that Boxers are particu-
larly prone to CD4+/CD45+ lymphoma without data
on the overall breed distribution of canine lymphoma,
we note that Boxers were not represented at all in our
companion study describing T zone lymphomas (Seelig
et ale). The aggressive clinical course described for the
majority of CD4+ lymphomas is compatible with ear-
lier work that has given rise to the concept that many
dogs with T-cell lymphoma have poor clinical out-
come. Importantly, a small but significant subset of
dogs with CD4+ lymphoma in this study had what
appeared to be a more indolent clinical course that
correlated with a unique surface immunophenotype
(CD4+/CD45).
The presence of hypercalcemia or mediastinal mass
did not have an impact on outcome in our cases of
CD4+/CD45+ lymphoma; these findings are similar to
previous published reports evaluating dogs with T-cell
lymphoma.12,13 Hypercalcemia and the presence of a
mediastinal mass are commonly recognized as negative
prognostic factors for dogs with lymphoma14; however,
our findings do not support this idea. Rather, these
data suggest that hypercalcemia and mediastinal
masses occur commonly with CD4+ T-cell lymphoma
and are not likely independent predictors of outcome
within this subtype.
Dogs in this study were treated with a variety of
chemotherapy protocols resulting in small sample sizes
within each treatment group, limiting our ability to
draw conclusions regarding the optimal treatment for
CD4+ T-cell lymphoma. However, our study does not
support the proposal that doxorubicin-containing pro-
tocols are less efficacious in the treatment of T-cell
lymphoma.12,15 There was no significant difference in
either PFI or OS in dogs treated with MOPP versus a
CHOP protocol. This is the first analysis of outcome
in T-cell lymphoma that focuses on a uniform immu-
nophenotype. Possible inclusion of indolent forms of
T-cell lymphoma in previous studies may have influ-
enced prior reported results. A randomized, prospec-
tive study evaluating MOPP versus CHOP as
treatment for a homogeneous population of dogs with
CD4+ T-cell lymphoma should be conducted to fur-
ther investigate optimal treatment for this disease.
Although our data show that CD4+/CD45+ T-cell
lymphoma is a highly aggressive form of lymphoma in
dogs regardless of the treatment chosen, flow cytomet-
ric characteristics did predict small but significant dif-
ferences in survival. Larger cell size of the neoplastic
CD4+/CD45+ lymphomas was associated with a signif-
icantly shorter PFI and overall survival. This remained
true in multivariable analysis when controlling for
other variables such as treatment, CD5 expression,
and clinical substage. Large cell size determined by
flow cytometry has been shown to be an independent
predictor of worse outcome in dogs with circulating
neoplastic B cells and in dogs with nodal B cell lym-
phomas.10,16 Larger cell size has also been associated
with worse outcome in human adult T-cell lymphoma
(ATL) and cutaneous PTCL.17,18 Loss of the surface
expression of the pan-T cell marker CD5 was a rela-
tively common finding within the CD4+/CD45+ lym-
phomas. Although both univariable and multivariable
analysis demonstrated a modest difference in overall
survival between CD5+ and CD5 cases, PFI was not
significantly different in either analysis. Loss of CD5
expression has been reported in human cases of PTCL
without any apparent effect on clinical outcome.19 The
true impact of CD5 expression on the prognosis of
canine CD4+/CD45+ lymphomas may require addi-
tional studies, but the loss of CD5 expression can serve
as a useful marker to classify these cells as neoplastic
in ambiguous cases.
A consistent finding in the CD4+/CD45+ lymphomas
in this study was a very low expression level of MHC
class II. Decreased surface expression of MHC class II
has been commonly associated with a worse clinical
outcome in human lymphoma20,21 and there is evidence
that this is true in canine B-cell lymphoma as well.10
The diminished MHC class II expression may prevent
adequate tumor immunosurveillance, which may have
played a role in the poor outcome of the majority
CD4+/CD45+, MHC class II low cases in this study.22
Cells from the CD4+/CD45+ cases expressed surface
CD3 and expressed either no MHC class II or only
low levels. By analogy with human T-cell lymphopro-
liferative disorders, these features suggest that the nor-
mal counterpart of this neoplasm is a T cell that has
completed its maturation, and is a single positive thy-
mocyte or a mature peripheral T cell.23 Comparisons
with human disease should be made cautiously, how-
ever, because expression of MHC class II is constitu-
tive in dogs24, whereas it is a feature only of activated
human T cells.25 This phenotype contrasts substan-
tially with that described for T zone lymphoma, which
expresses high levels of class II MHC, CD25, and
CD21, all of which point to an activated phenotype
(Seelig et ale). More studies are needed to definitively
establish the normal counterpart of these cells, but
such knowledge should help us better understand the
genesis of this disease.
The subset of 15 CD4+/CD45+ cases that had tissue
available for histologic assessment was categorized as
either PTCL or LBT. Recognizing the limitations of
small sample numbers, there were no obvious differ-
ences in clinical presentation or outcome between these
2 histologic subtypes. A recent paper examining gene
expression profiles in a small number of canine lym-
phoma cases suggests that both PTCL and LBT have
similar gene expression profiles and may represent a
continuum of the same disease.26 Work comparing
surface phenotype with the Kiel cytologic classification
in a small subset of canine T-cell lymphomas found
that 5/8 small clear cell (T zone correlate) and 5/5
pleomorphic mixed small and large (PTCL correlate)
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tumors expressed surface CD4.4 Interestingly, 5/8 of
the small clear cell/T zone cases had dim or absent
CD45 expression and one of the small clear cell/T zone
cases expressed low levels of CD21. Although we did
not have tissue available from any of the CD4+/
CD45 cases, work from our laboratory presented in
a concurrent manuscript and a recent report has
shown that the surface phenotype of this group
(CD45/MHC class II high/CD21+) correlates with T
zone histology (Seelig et ale).6
In this study, we have demonstrated that the major-
ity of canine CD4+ T-cell lymphomas with peripheral
lymph node involvement have an aggressive clinical
course and share many of the clinical features com-
monly reported in previous studies of T-cell lym-
phoma. These lymphomas expressed low levels of
MHC class II and variable levels of the pan-T cell
marker CD5 and were histologically classified as both
PTCL and LBT. Importantly, we have identified a
small subset of CD4+ T-cell lymphomas that express a
unique surface phenotype characterized by an absence
of CD45, coexpression of CD21, and high MHC class
II expression that appear to have a much more indo-
lent overall clinical course. Our concurrent study (See-
lig et ale) and a recent publication6 indicated that this
phenotype is consistent with T zone lymphoma. Three
dogs with the CD4+/CD45 phenotype had overall
survival times similar to the CD4+/CD45+ cases and,
although we do not know the exact reason these ani-
mals were euthanized, this could be compatible with
the recent suggestion that indolent lymphomas may
behave more aggressively if diagnosed at more
advanced stages.27
The 2 diseases described in this study and in the
companion paper (Seelig et ale) represent 2 ends of the
spectrum of T-cell disease. T zone lymphoma is gener-
ally characterized by a prolonged clinical course, and
there are data to support the idea that CHOP chemo-
therapy is no more effective than treatment with
prednisone and chlorambucil.28 CD4+/CD45+ T-cell
lymphoma is aggressive, and although multi drug
treatment extends survival, the majority of patients die
of their disease by 300 days. This study demonstrates
the practical utility of flow cytometry as a noninvasive
diagnostic tool and reiterates the importance of
subclassification of canine lymphomas beyond B versus
T-cell phenotype.
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